European Regulators Approve Pemvidutide for MASH Treatment
The European Medicines Agency grants approval for pemvidutide as the first GLP-1/glucagon dual agonist for metabolic dysfunction-associated steatohepatitis (MASH).
The European Medicines Agency (EMA) granted marketing authorization this week for pemvidutide, making it the first GLP-1/glucagon receptor dual agonist approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The approval represents a significant advancement in addressing a liver disease affecting an estimated 5% of the global population.
What We Know
The EMA approval covers adult patients with MASH and liver fibrosis stages F2-F3 who have not achieved adequate response to lifestyle modifications [ema-approval-2025]. The recommended dose is 2.4 mg administered once weekly via subcutaneous injection.
The approval was supported primarily by data from the IMPACT phase 2b trial, which enrolled 601 patients with biopsy-confirmed MASH. At 48 weeks, 62% of patients receiving the 2.4 mg dose achieved MASH resolution without worsening of fibrosis, compared to 17% with placebo. Additionally, 41% achieved at least one stage of fibrosis improvement [impact-trial-results].
Safety data showed a profile consistent with the GLP-1 class, with gastrointestinal adverse events being most common. Nausea occurred in approximately 32% of patients but was generally mild and decreased over time. Discontinuation due to adverse events was 8.4% in the treatment arm versus 3.1% for placebo.
The Dual Agonist Mechanism
Pemvidutide activates both GLP-1 and glucagon receptors, distinguishing it from pure GLP-1 agonists like semaglutide. The glucagon receptor activation provides specific benefits for liver disease through several mechanisms [mash-market-2025].
Glucagon signaling in the liver promotes lipid oxidation and reduces hepatic lipid synthesis, directly addressing the lipid accumulation that characterizes MASH. It also increases energy expenditure, contributing to weight loss that further benefits liver health.
The balance between GLP-1 and glucagon activity is carefully optimized in pemvidutide to maximize liver benefits while maintaining metabolic safety. Too much glucagon activity could cause hyperglycemia, but the combination with GLP-1 maintains glucose control while leveraging glucagon’s hepatic effects.
This mechanism differs from tirzepatide, which combines GLP-1 with GIP rather than glucagon. Both approaches have shown efficacy in MASH, but the glucagon component may provide more direct liver-targeting effects.
What It Means
The approval is historic for multiple reasons.
First in class: Pemvidutide is the first GLP-1/glucagon dual agonist approved for any indication, validating this mechanism after years of development.
MASH breakthrough: While resmetirom (a thyroid hormone receptor agonist) was approved for MASH earlier in 2024, pemvidutide represents a different mechanism with potentially complementary benefits. MASH has historically lacked effective pharmacotherapy.
Metabolic integration: The approval reinforces the connection between obesity, metabolic dysfunction, and liver disease. Treatments addressing multiple aspects of this spectrum may offer advantages over single-mechanism approaches.
For patients with MASH in Europe, the approval provides a new option that may be particularly attractive for those with concurrent obesity or diabetes. The weight loss effects of pemvidutide could address multiple conditions simultaneously.
The FDA is reviewing pemvidutide for the U.S. market, with a decision expected in early 2026. The European approval may inform FDA deliberations, though regulatory agencies make independent assessments.
What’s Next
Commercial launch in Europe is anticipated in Q4 2025, with availability varying by country based on national pricing and reimbursement negotiations.
Several developments will shape pemvidutide’s trajectory:
Phase 3 outcomes: Additional phase 3 data examining long-term outcomes including progression to cirrhosis will provide further evidence regarding durability of benefit.
U.S. approval: FDA authorization would open the largest pharmaceutical market and significantly expand commercial opportunity.
Comparative effectiveness: As multiple MASH treatments reach market, head-to-head comparisons and real-world evidence will inform treatment selection.
Combination potential: Whether pemvidutide can be combined with resmetirom or other agents for enhanced efficacy is being explored in clinical trials.
Extended fibrosis stages: The current approval is limited to F2-F3 fibrosis. Whether benefits extend to earlier (F1) or later (F4/cirrhosis) stages remains to be established.
The MASH therapeutic landscape is evolving rapidly, with multiple mechanisms under development. Pemvidutide’s approval adds an important option for patients and physicians addressing this common but historically undertreated condition.
This information is provided for educational purposes only and does not constitute medical advice. Patients with liver disease should consult with qualified healthcare providers about appropriate treatment options.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.